Netarsudil Ophthalmic Clinical Trials (2026): 31 Studies for Ocular Hypertension & Open Angle Glaucoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
31 Netarsudil Ophthalmic clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 15 indications (including Ocular Hypertension & Open Angle Glaucoma) and 4,940 total planned enrollment. 6 Phase 3 Netarsudil Ophthalmic trials and 6 Phase 2, 8 Phase 4 are listed. 6 Netarsudil Ophthalmic clinical trials are actively recruiting at 3 U.S. sites across 3 states. Most recent activity: NCT07588152 (Jun 2028).
Where to Participate: All Netarsudil Ophthalmic Trial Sites in the U.S. (3 sites across 3 states)
Every actively recruiting Netarsudil Ophthalmictrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| IN | Indiana Universtiy School of Optometry | Bloomington47405 | NCT07588152 | Map |
| MA | Mass Eye and Ear | Boston02114 | NCT06033703 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT07325240 | Map |
Netarsudil Ophthalmic clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|---|
| Early P1 | 2 | 1 | 3 | |||||
| P1 | 1 | 1 | ||||||
| P1/P2 | 1 | 1 | ||||||
| P2 | 6 | 6 | ||||||
| P2/P3 | 1 | 1 | 1 | 3 | ||||
| P3 | 6 | 6 | ||||||
| P4 | 2 | 1 | 3 | 1 | 1 | 8 | ||
| N/A | 2 | 1 | 3 |
Recruiting Netarsudil Ophthalmic clinical trials (6)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07588152 | Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension | P4 | Glaucoma | 50 | Jun 2026 |
| NCT07325240 | 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients | P4 | Open Angle Glaucoma | 30 | Nov 2025 |
| NCT07048886 | Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) | P4 | Primary Open Angle Glaucoma | 68 | Jul 2025 |
| NCT06033703 | Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment | P1/P2 | Rhegmatogenous Retinal Detachment | 48 | Jan 2025 |
| NCT06969586 | The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy | — | Fuchs Endothelial Corneal Dystrophy | 50 | Apr 2025 |
| NCT06960629 | PBKThe Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) | — | Pseudophakic Bullous Keratopathy | 50 | Apr 2025 |
Netarsudil Ophthalmic clinical trials by indication
Open Angle Glaucoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07325240 | — | P4 | recruiting | 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients |
| NCT06441643 | — | P2 | completed | Next Generation Rocklatan |
| NCT03284853 | — | P3 | completed | Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension |
| NCT03844945 | — | P2 | completed | Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan |
| NCT02057575 | — | P2 | completed | Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure |
Fuchs' Endothelial Dystrophy (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04752020 | — | Early P1 | completed | Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty |
| NCT03971357 | — | P2/P3 | terminated | Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration |
| NCT04057053 | — | Early P1 | completed | Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty |
| NCT03248037 | — | P3 | completed | Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation |
Ocular Hypertension (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07082816 | — | P3 | completed | Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction |
| NCT04401982 | — | N/A | completed | Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects |
| NCT02874846 | — | P2 | completed | Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution |
Glaucoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07588152 | — | P4 | recruiting | Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension |
| NCT05283395 | — | P4 | completed | Rocklatan® Evaluation |
Primary Open Angle Glaucoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07048886 | — | P4 | not yet recruiting | Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) |
| NCT04620135 | — | P3 | completed | Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension |
Primary Open Angle Glaucoma or Ocular Hypertension (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06865144 | IOP | P4 | active not recruiting | Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT |
| NCT03233308 | POAG | P2 | completed | Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) |
Rhegmatogenous Retinal Detachment (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06033703 | — | P1/P2 | recruiting | Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment |
| NCT05660447 | — | P2/P3 | active not recruiting | A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR |
Normal Tension Glaucoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06449352 | — | P4 | completed | Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost |
| NCT04981886 | NTG | P4 | unknown | Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma |
Glaucoma, Open-Angle (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04234932 | — | Early P1 | unknown | Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation |
| NCT03808688 | — | P4 | completed | Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting |
Open-angle Glaucoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02558400 | — | P3 | completed | Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension |
| NCT02674854 | — | P3 | completed | Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension |
Fuchs Endothelial Corneal Dystrophy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06969586 | — | N/A | enrolling by invitation | The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy |
Pseudophakic Bullous Keratopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06960629 | PBK | N/A | enrolling by invitation | The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) |
Corneal Edema (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04498169 | Fuchs | P2 | completed | A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy |
Fuchs Endothelial Dystrophy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04051463 | — | P2/P3 | completed | Rhopressa for Corneal Edema Associated With Fuchs Dystrophy |
Healthy Subjects (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02406287 | — | P1 | completed | A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers |
Netarsudil Ophthalmic pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| IOP | NCT06865144 | P4 | active not recruiting | Primary Open Angle Glaucoma or Ocular Hypertension | 70 | PMID 12049574 |
| NTG | NCT04981886 | P4 | unknown | Normal Tension Glaucoma | 115 | — |
| Fuchs | NCT04498169 | P2 | completed | Corneal Edema | 40 | PMID 36327101 |
| POAG | NCT03233308 | P2 | completed | Primary Open Angle Glaucoma or Ocular Hypertension | 20 | — |
Terminated and withdrawn Netarsudil Ophthalmic trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT03971357terminatedTrial of Netarsudil for Acceleration of Corneal Endothelial Restoration
All Netarsudil Ophthalmic trials (31)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07588152 | Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension | P4 | recruiting | 50 | Indiana University | Jun 2026 | |
| NCT07325240 | 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients | P4 | recruiting | 30 | Mayo Clinic | Nov 2025 | |
| NCT07048886 | Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) | P4 | not yet recruiting | 68 | Center for Sight Las Vegas | Jul 2025 | |
| NCT06033703 | Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment | P1/P2 | recruiting | 48 | Massachusetts Eye and Ear Infirmary | Jan 2025 | |
| NCT06969586 | The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy | — | enrolling by invitation | 50 | University Hospital Dubrava | Apr 2025 | |
| NCT06960629 | PBK | The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) | — | enrolling by invitation | 50 | University Hospital Dubrava | Apr 2025 |
| NCT06865144 | IOP | Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT | P4 | active not recruiting | 70 | East Coast Institute for Research | Jun 2025 |
| NCT07082816 | Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction | P3 | completed | 489 | Alcon Research | Sep 2025 | |
| NCT06441643 | Next Generation Rocklatan | P2 | completed | 426 | Alcon Research | Sep 2024 | |
| NCT06449352 | Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost | P4 | completed | 100 | Westlake Eye Specialists | Jun 2024 | |
| NCT05660447 | A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR | P2/P3 | active not recruiting | 80 | Wills Eye | Feb 2023 | |
| NCT04752020 | Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty | Early P1 | completed | 25 | Massachusetts Eye and Ear Infirmary | Mar 2021 | |
| NCT05283395 | Rocklatan® Evaluation | P4 | completed | 136 | Aerie Pharmaceuticals | Mar 2022 | |
| NCT04981886 | NTG | Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma | P4 | unknown | 115 | Salus University | Aug 2021 |
| NCT04401982 | Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects | — | completed | 10 | University of Maryland, Baltimore | Mar 2021 | |
| NCT03971357 | Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration | P2/P3 | terminated | 19 | Price Vision Group | Jul 2019 | |
| NCT04498169 | Fuchs | A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy | P2 | completed | 40 | Aerie Pharmaceuticals | Sep 2020 |
| NCT04620135 | Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension | P3 | completed | 245 | Aerie Pharmaceuticals | Nov 2020 | |
| NCT04234932 | Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation | Early P1 | unknown | 10 | University of the Incarnate Word | Jan 2020 | |
| NCT04057053 | Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty | Early P1 | completed | 10 | Massachusetts Eye and Ear Infirmary | Oct 2018 | |
| NCT03284853 | Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension | P3 | completed | 436 | Aerie Pharmaceuticals | Sep 2017 | |
| NCT04051463 | Rhopressa for Corneal Edema Associated With Fuchs Dystrophy | P2/P3 | completed | 29 | Price Vision Group | Aug 2019 | |
| NCT03844945 | Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan | P2 | completed | 215 | Aerie Pharmaceuticals | Mar 2019 | |
| NCT03808688 | Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting | P4 | completed | 261 | Aerie Pharmaceuticals | Dec 2018 | |
| NCT03248037 | Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation | P3 | completed | 120 | Cornea Research Foundation of America | Sep 2017 | |
| NCT03233308 | POAG | Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) | P2 | completed | 20 | Aerie Pharmaceuticals | Oct 2017 |
| NCT02558400 | Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension | P3 | completed | 718 | Aerie Pharmaceuticals | Sep 2015 | |
| NCT02674854 | Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension | P3 | completed | 750 | Aerie Pharmaceuticals | Feb 2016 | |
| NCT02874846 | Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution | P2 | completed | 12 | Aerie Pharmaceuticals | Jul 2016 | |
| NCT02406287 | A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers | P1 | completed | 10 | Aerie Pharmaceuticals | Apr 2015 | |
| NCT02057575 | Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure | P2 | completed | 298 | Aerie Pharmaceuticals | Jan 2014 |
Netarsudil Ophthalmic clinical trials: frequently asked questions
- How many Netarsudil Ophthalmic clinical trials are there?
- 31 Netarsudil Ophthalmic clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 20 are marked completed.
- Are Netarsudil Ophthalmic clinical trials recruiting in 2026?
- Yes — 5 Netarsudil Ophthalmic trials are actively recruiting in 2026, with 3 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Netarsudil Ophthalmic being studied for?
- Netarsudil Ophthalmic is being studied for Ocular Hypertension, Open Angle Glaucoma, Glaucoma, Fuchs' Endothelial Dystrophy, Open-angle Glaucoma and 14 more. The trials are grouped by indication on this page.
- What phase is Netarsudil Ophthalmic in?
- Netarsudil Ophthalmic clinical trials span 8 Phase 4, 6 Phase 3, 6 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Netarsudil Ophthalmic clinical trials?
- The lead sponsor across the most Netarsudil Ophthalmic trials is Aerie Pharmaceuticals, with 14 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Netarsudil Ophthalmicas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: